Should patients with ALL undergo HSCT after CAR T-cell therapy?HealioCAR T-cell therapies for ALL hold great promise, yielding remission rates of up to 90% for relapsed/refractory patients. However, the durability of these responses remains uncertain, … Continue reading
Genetic Literacy ProjectCRISPR update calms fears about off-target editing effectsGenetic Literacy ProjectA study last year involving just three mice raised fears that CRISPR-Cas9, the classic version of the genome editor, might be a big, stupid bloodh… Continue reading
Parkinson’s News Today |
Second Parkinson’s Group in Phase 1 Trial Receives ISCO’s Neural Stem Cell Therapy
Parkinson’s News Today A second group of Parkinson’s patients in a Phase 1 clinical trial have received International Stem Cell Corporation’s neural stem cell therapy. The main goal of the trial (NCT02452723) at Royal Melbourne Hospital is to see whether ISCO’s stem cell … |
Drug Target Review |
CRISPR/Cas9 technique suppresses malaria infection in mosquitos
Drug Target Review Using a gene-editing technique known as CRISPR/Cas9, scientists have shown that inactivating the gene FREP1 reduces mosquitos’ susceptibility to infection with Plasmodium, a genus of parasites that causes malaria in humans. Inside an Anopheles gambiae … |